Skip to main content

Biohaven Ltd 10-Q for FY2026 Q3

Biohaven Ltd. (BHVN)

10-Q 2026-10-29 For: 2026-09-30
View Original
Added on October 29, 2026

About this 10-Q

Biohaven Ltd filed this 10-Q on October 29, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

In August 2026, Biohaven agreed to license its Kv7 ion channel platform, including BHV-7000, worldwide to SK Biopharmaceuticals. SKBP will pay a non-creditable and non-refundable upfront fee of $400.0 million, $350.0 million at Closing and $50.0 million one year later, plus up to $150.0 million in milestones. An FDA partial clinical hold dated September 4, 2026 pauses new patient enrollment pending additional metabolite nonclinical data. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$129.28M
compared with a net loss of $173.44M a year earlier
Diluted EPS
-$0.86
compared with -$1.64 a year earlier